Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT03778944
Recruiting Not applicable

Enhancing Renal Graft Function During Donor Anesthesia

NCT03778944 · tracked via the Priya Life Science Egypt tracker
Sponsor
Nazmy Edward Seif
Phase
Not applicable
Started
2018-12-20
Last updated
2026-01-12

Condition(s) studied

Renal Failure ChronicTransplant;Failure,KidneyAnesthesia

Investigational drug(s) / intervention(s)

Mannitol infusionDopamine infusionAdequate hydration

Mannitol infusion: Infusion of Mannitol 20% at a dose of 0.5 mg/kg to the renal graft donor after induction of anesthesia over 15 minutes.

Dopamine infusion: Infusion of Dopamine at a dose of 4 microg/kg/min to the renal graft donor after induction of anesthesia till ligation of the renal artery.

Adequate hydration: Infusion of Ringer Acetate at a rate of 15 ml/kg/hr to the renal graft donor after induction of anesthesia till ligation of the renal artery.

Study summary

Renal transplantation is now recognized as the treatment of choice for patients with end-stage renal disease. An optimum anesthetic regimen should enhance the function and perfusion of the transplanted kidney. The aim of this study is to assess \& compare the effectiveness of 3 different modalities in this respect: Mannitol, Dopamine and adequate hydration.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * end-stage renal disease, for living-donor kidney transplantation Exclusion Criteria: * severe cardiac or hepatic dysfunction * coagulopathy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Kasr Al-Ainy Hospital, Cairo University Cairo Egypt Recruiting

More Nazmy Edward Seif trials in Egypt

Mannitol Versus Nitroglycerin for Kidney Injury Prevention in Robotic-assisted Radical Prostatectomy or Cystectomy Active, not recruiting
Low-Thoracic Epidural Anesthesia For Laparoscopic Nephrectomy. Recruiting
Continuous Spinal Anesthesia in Renal Transplantation Active, not recruiting
Lung US for PEEP Optimization in Robotic Radical Prostatectomy or Cystectomy Patients Active, not recruiting
Electric Cardiometry-Guided Standard Versus Restricted Fluid Therapy In Robotic Prostaectomy Recruiting

Other trials for the same condition

Effect of Total Intravenous Anesthesia vs Inhalational Anesthesia on the Level of Inflammatory Markers Active, not recruiting
The Effect of Opioid Free Anesthesia Using Ultrasound-Guided Bilateral Transversus Abdominus Plane Block and Dexmedetomidine Infusion Starting soon
Total Intravenous Anesthesia in Patients Undergoing Craniotomy Active, not recruiting
Low-Thoracic Epidural Anesthesia For Laparoscopic Nephrectomy. Recruiting
Continuous Spinal Anesthesia in Renal Transplantation Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03778944 on ClinicalTrials.gov ↗ ← All trials in Egypt